Nosoh Y, Nishiyama M, Yamaguchi M, Hirabayashi N, Toge T, Niimoto M, Hattori T
Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 2):1221-6.
A rapid method using nude mice has been established as an in vivo model for assessing the chemosensitivity of individual human tumors, in which the final evaluation is made with 3H-thymidine (3H-TdR) incorporation into the treated tumor. In 234 of 289 cancers, the chemosensitivity of anticancer agents was evaluated by this method. This assay proved to be feasible in a sufficiently high percentage of human primary tumors (81.0%). The rate of positive sensitivity against all tumors was 23.8% for MMC, 12.3% for 5-FU, 29.1% for CPM and 23.5% for ADM, respectively. The sensitivity of anticancer agents varied according to the type of cancer. Correlation between the sensitivity test and the end results after chemotherapy in cases of inoperable gastrointestinal cancers was investigated, prospectively. Out of 19 cases, the 50% survival time of 11 patients treated with sensitive agents was longer than that of 8 patients treated with insensitive agents. From a prospective-correlative study carried out on 25 patients, this assay appeared to be correlated with clinical response (overall agreement, 76.0%) with specific agreements of sensitivity and resistance of 37.5% and 94.1%, respectively. From these results, it seems reasonable to conclude that this sensitivity test using a human/nude mouse system is a useful screening assay for revealing appropriate agents for the treatment of patients with cancer.
一种利用裸鼠的快速方法已被确立为评估个体人类肿瘤化学敏感性的体内模型，其中最终评估是通过将³H-胸腺嘧啶核苷（³H-TdR）掺入经治疗的肿瘤来进行的。在289例癌症中的234例中，采用该方法评估了抗癌药物的化学敏感性。该检测方法在足够高比例的人类原发性肿瘤中（81.0%）被证明是可行的。对所有肿瘤的阳性敏感率，丝裂霉素（MMC）为23.8%，5-氟尿嘧啶（5-FU）为12.3%，环磷酰胺（CPM）为29.1%，阿霉素（ADM）为23.5%。抗癌药物的敏感性因癌症类型而异。对无法手术的胃肠道癌症患者，前瞻性地研究了敏感性检测与化疗最终结果之间的相关性。在19例患者中，接受敏感药物治疗的11例患者的50%生存时间长于接受不敏感药物治疗的8例患者。在对25例患者进行的前瞻性相关性研究中，该检测方法似乎与临床反应相关（总体一致性为76.0%），敏感性和耐药性的具体一致性分别为37.5%和94.1%。从这些结果来看，得出以下结论似乎是合理的：这种使用人/裸鼠系统的敏感性检测对于为癌症患者揭示合适的治疗药物是一种有用的筛选检测方法。
